PHE Senior Research Economist James Baumgardner, PhD, and colleagues conducted an analysis aimed at determining whether spending within oncology care episodes is associated with survival. (more…)
As a guest contributor to Clinical Leader, Precision for Value’s Dominic Galante examines the importance of payer perspective during clinical R&D. With a greater push for evidence-based value, scientists are starting to incorporate payer insights earlier in drug development.
The Bipartisan Budget Act of 2018 (BBA 2018) directly affects Medicare Part D drugs, but its impact could expand beyond. Precision for Value’s Joanne Mai and Andrew Cournoyer cover how this change in the Medicare coverage gap program represents a small step toward encouraging biosimilar development, containing drug prices, and improving patient access. (more…)
In the Journal of Clinical Pathways our experts identify key factors influencing the implementation of value-based contracting. (more…)
As the US healthcare landscape continues to change at a rapid rate, Kellie Rademacher and Jeremy Schafer take a closer look at the emerging trend of vertical integration. (more…)
In an article in Managed Care, Jeremy Schafer discusses the findings from a recent breast cancer study reported in JAMA. (more…)
Led by a team of PHE researchers, a new study appearing in the American Journal of Managed Carehas determined that long-term cancer survivors can expect health and quality of life on par with Americans of the same age and background. (more…)
In a recent column in Health Affairs, Precision’s Jason Shafrin and Mark Linthicum address how value assessment frameworks are leading to more patient-centered formularies.
Phil Cyr and Larry Blandford offer their experience and insights on developing health economic models for gene and cellular therapies. (more…)
Precision’s All Access is our bimonthly newsletter with original content written by our payer experts for market access leaders. (more…)
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
